Levodopa News and Research

RSS
Promising results for multi-source DBS in Parkinson’s disease

Promising results for multi-source DBS in Parkinson’s disease

New treatment shows promise in easing symptoms of Parkinson's disease

New treatment shows promise in easing symptoms of Parkinson's disease

Bilirubin levels raised in newly diagnosed Parkinson’s disease

Bilirubin levels raised in newly diagnosed Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Perceived cost affects placebo response in Parkinson’s disease

Perceived cost affects placebo response in Parkinson’s disease

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Researchers close to novel therapy to treat levodopa-induced dyskinesia

FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron, Zambon announce re-submission of safinamide NDA to FDA

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists may be safe for the heart

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax announces submission of EMA Marketing Authorization Application for IPX066

Levodopa dose linked to malnutrition risk in Parkinson’s disease

Levodopa dose linked to malnutrition risk in Parkinson’s disease

NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm signs definitive investment agreements for $16 million financing round

Study: Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Study: Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Sleep problems in PD patients can worsen in later stages of disease

Sleep problems in PD patients can worsen in later stages of disease

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

Study heterogeneity hinders mortality predictions in Parkinson’s disease

Study heterogeneity hinders mortality predictions in Parkinson’s disease